Advertisement

Topics

Safety, Tolerability, Biomarker and Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis

2014-08-27 03:12:42 | BioPortfolio

Summary

PUR 0110 is a 100% natural novel investigational medicinal product that has been demonstrated in several in vitro and in vivo pharmacology studies to have potent anti-inflammatory, anti-oxidative and immunomodulatory effects. This exploratory Phase 2a study is a first-in-patient study to evaluate the safety, tolerability, biomarker effect and efficacy of PUR 0110 rectal enema in patients with active mild-to-moderate distal ulcerative colitis (UC).

The study is a multicenter, randomized, double-blind, parallel-group, dose-ranging, placebo-controlled study. To be eligible for inclusion into the study, patients must either be newly diagnosed or have on-going active mild-to-moderate distal ulcerative colitis of at least 3 months duration confirmed in either case by flexible sigmoidoscopy and biopsy at the Screening Visit. In addition, patients must have a modified Mayo score of ≥5 to ≤10 including a sigmoidoscopy inflammation grade and rectal bleeding scores of ≥2 each. Eligible patients will be randomly assigned to receive either PUR 0110 250 mg, 500 mg or 1000 mg or placebo rectal enema in a 1:1:1:1 ratio. Patients will self-administer the assigned study medication intrarectally once-daily at bedtime (10:00 p.m +/- 1 hour) for 2 weeks.

Patients will be evaluated for safety by adverse events, clinical laboratory tests, vital signs, physical examination, electrocardiogram (ECG), and concomitant medications. Efficacy evaluations will include the modified Mayo score, patient-defined response and remission, Investigator Assessment of Ulcerative Colitis Symptom Score, Inflammatory Bowel Disease Questionnaire (IBDQ), and biomarkers of inflammation, apoptosis and total cell death, lipid peroxidation and in vivo oxidative stress, and antioxidant defense mechanisms in plasma, serum, urine, feces and biopsy tissue. Patients will have a flexible sigmoidoscopy and biopsy 12 hours after the last dose of study medication.

Description

Safety/Primary Outcome Parameters:

- Incidence, nature and severity of adverse events

- Incidence, nature and severity of clinical laboratory test abnormalities

Efficacy/Secondary Outcome Parameters:

- Clinical remission defined as an endoscopy score of ≤ 1, a rectal bleeding score of 0, and an improvement or no change from baseline in the stool frequency score at the end of 2 weeks of treatment / withdrawal visit;

- Clinical response rate defined as the percentage of patients with a drop of ≥3 points from the baseline overall modified Mayo score;

- Patient defined response and remission rates;

- Change from baseline in the overall modified Mayo score (Disease Activity Index);

- Change from baseline in each of the 4 individual sub-scores of the modified Mayo score;

- Change from baseline in Investigator Assessment of UC Symptom Score (total and individual symptom scores)

- Change from baseline in IBDQ score (total and the 4 individual dimension scores)

- Proportion of patients with treatment failure;

- Change from baseline in serum lutein levels;

- Change from baseline in C-reactive protein (CRP), high sensitivity CRP (hs-CRP), erythrocyte sedimentation rate (ESR), fecal calprotectin (FCP), and fecal lactoferrin (FL).

- Change from baseline in exploratory biomarkers including: serum interleukin-2 (IL-2), IL-6, IL-8, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-beta), IL-4, IL-10, IL-17, IL-23, human beta-Defensin-2 (hBD-2), malondialdehyde (MDA), lipoxin A4 (LXA4), glutathione (GSH), M30 and M65 apoptosomes in serum and biopsies, and plasma and urinary isoprostane levels.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Conditions

Left-Sided Ulcerative Colitis

Intervention

PUR 0110 Rectal Enema 250 mg, PUR 0110 Rectal Enema 500 mg, PUR 0110 Rectal Enema 1000 mg, Placebo Enema

Location

PurGenesis Investigational Site
Essen-Werden
Germany
45239

Status

Recruiting

Source

PurGenesis Technologies Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:42-0400

Clinical Trials [812 Associated Clinical Trials listed on BioPortfolio]

Mesalamine 4 gm/60 mL Rectal Enema

The objective of this study is to evaluate the relative bioavailability of the test formulation of mesalamine suspension rectal enema with the already marketed reference formulation Rowasa...

Bioavailability Study of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations

The purpose of this study is to evaluate the relative bioavailability of the test formulation of mesalamine suspension rectal enema with the reference formulation in healthy, adult subject...

Microbial Restoration for Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

Multi-center, randomized, placebo controlled, partially blinded trial comparing the safety and efficacy of fecal microbiota transplantation versus placebo both delivered by rectal enema in...

Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing

In order for flexible sigmoidoscopy to be a successful screening procedure, the bowel must be free of solid matter so the endoscopist has a clear view, increasing the chance of detection o...

A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials

Microbicides are drugs that destroy microbes such as viruses and bacteria. Rectal microbicides may be able to prevent transmission of HIV during anal intercourse. The purpose of this study...

PubMed Articles [415 Associated PubMed Articles listed on BioPortfolio]

Effect of rectal douching/enema on rectal gonorrhoea and chlamydia among a cohort of men who have sex with men on HIV pre-exposure prophylaxis.

Rectal douching/enema (RD) is a common practice among men who have sex with men (MSM) in preparation for sex. RD can break down the rectal mucosal barrier and potentially affect the rectal microbiome....

Retrieval of a large rectal ESD-specimen using bowel preparation after unsuccessful rectal enema. First report of a novel technique.

Endoscopic submucosal dissection (ESD) is an effective procedure for the treatment of large colorectal lesions, with excellent en-bloc resection and local recurrence rates [1]. In large and bulky lesi...

Rectal wall MRI radiomics in prostate cancer patients: Prediction of and correlation with early rectal toxicity.

To investigate MRI radiomic analysis to assess IMRT associated rectal wall changes and also for predicting radiotherapy induced rectal toxicity.

Comparison of Anal Versus Rectal Staging in the Prognostication of Rectal Squamous Cell Carcinoma: A Population-Based Analysis.

Rectal squamous cell carcinoma is a rare malignancy with limited data regarding management and prognosis. It is also unknown whether a rectal squamous cell cancer staging system should be based on siz...

LncRNA NKILA correlates with the malignant status and serves as a tumor-suppressive role in rectal cancer.

NF-κB interacting lncRNA (NKILA) has been found to function as a tumor-suppressive role in various human cancers. However, the role of NKILA in rectal cancer is still unknown. The objective of this s...

Medical and Biotech [MESH] Definitions

A compound tubular gland, located around the eyes and nasal passages in marine animals and birds, the physiology of which figures in water-electrolyte balance. The Pekin duck serves as a common research animal in salt gland studies. A rectal gland or rectal salt gland in the dogfish shark is attached at the junction of the intestine and cloaca and aids the kidneys in removing excess salts from the blood. (Storer, Usinger, Stebbins & Nybakken: General Zoology, 6th ed, p658)

Protrusion of the rectal mucous membrane through the anus. There are various degrees: incomplete with no displacement of the anal sphincter muscle; complete with displacement of the anal sphincter muscle; complete with no displacement of the anal sphincter muscle but with herniation of the bowel; and internal complete with rectosigmoid or upper rectum intussusception into the lower rectum.

Uptake of substances from the RECTUM.

Tumors or cancer of the RECTUM.

Procedure involving the instillation of an anesthetic into the rectum.

More From BioPortfolio on "Safety, Tolerability, Biomarker and Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial